Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | BAX | Q07812 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PTPRA | P18433 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495526 | 0.87 | ALDH1A1 (0.40) | GAAPTGS2APAF1ALDH1A1CYP1A2 | |
| SCHEMBL3491785 | 0.84 | PKM (0.47) | TSHRPKMGAAPTGS2APAF1 | |
| SCHEMBL3494226 | 0.77 | APAF1 (0.38) | TSHRPKMGAAAPAF1ALDH1A1 | |
| SCHEMBL3494223 | 0.72 | CYP2D6 (0.38) | ALDH1A1CYP1A2BAXKDM4EPOLB | |
| SCHEMBL5794357 | 0.70 | PKM (0.52) | TSHRPKMGAAPTGS2ALDH1A1 | |
| SCHEMBL4454418 | 0.67 | ALDH1A1 (0.49) | TSHRGAAALDH1A1CYP1A2KDM4E | |
| SCHEMBL4454414 | 0.67 | ALDH1A1 (0.49) | TSHRGAAALDH1A1CYP1A2KDM4E | |
| SCHEMBL20028090 | 0.66 | NSD3 (0.50) | TSHRPKMGAAPTGS2ALDH1A1 | |
| SCHEMBL4799247 | 0.65 | DGAT1 (0.41) | TSHRPKMGAAPTGS2 | |
| SCHEMBL25297365 | 0.65 | PTPRA (0.56) | TSHRGAAALDH1A1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | TSHR 684/4885PKM 1279/4885GAA 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.